It has come to light that cancer cells are able to become resistant to therapies by recruiting the use of a similar, compensatory pathway that continue downstream activation of protein synthesis, i.e., the AKT pathway, and/or transcriptional up-regulation of survival genes mediated by the MAPK pathway. Here, AKT1 is linked to cancer.